A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Status:
Terminated
Trial end date:
2018-09-26
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate objective response rate ([ORR]: complete
response [CR] and partial response [PR]) by investigator review in participants with
anaplastic thyroid cancer (ATC) treated with lenvatinib.